Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Novelwise Pharmaceutical Corporation
Parabilis Medicines, Inc.
NaviFUS Corporation
Stemline Therapeutics, Inc.
Baptist Health South Florida
Essen Biotech
Essen Biotech
Australian & New Zealand Children's Haematology/Oncology Group
Eli Lilly and Company
PharmaMar
In8bio Inc.
University Hospital, Basel, Switzerland
Northwell Health
Northwell Health
Northwell Health
VBI Vaccines Inc.
BeiGene
Aminex Therapeutics, Inc.
Basilea Pharmaceutica
The First Affiliated Hospital with Nanjing Medical University
TVAX Biomedical
Bristol-Myers Squibb
Boston Scientific Corporation
Accendatech USA Inc.
Proximagen, LLC
Novartis
Second Affiliated Hospital, School of Medicine, Zhejiang University
University of Regensburg
Celgene
AHS Cancer Control Alberta
National Institutes of Health Clinical Center (CC)
Hadassah Medical Organization
BBB-Therapeutics B.V.
INSYS Therapeutics Inc
Visualase, Inc.